Adjuvant Chemotherapy versus Radiotherapy in High-risk, Early-stage Endometrioid Endometrial Carcinoma

Abstract

Objective

The present study was designed to evaluate the effects of adjuvant chemotherapy (CT) vs. radiotherapy (RT, alone or combined with CT) on the prognosis of patients with high-risk, early-stage (stage I and stage II) endometrioid endometrial carcinoma.

Methods

This single-center retrospective clinical study was conducted in Union Hospital, Tongji Medical College, Huazhong University of Science and Technology between 2010 and 2019. In the present study, endometrioid endometrial carcinoma patients, who underwent total hysterectomy and bilateral salpingo-oophorectomy followed by postoperative adjuvant CT or RT (alone or combined with CT), and were diagnosed with stage IA grade 2/3 with lymph-vascular space invasion (LVSI), and stage IB with two or more uterine risks, including old age, histological grade 2 or 3, LVSI and stage II, were included. According to the postoperative adjuvant therapy, all eligible patients were divided into two groups: CT group and RT (RT±CT) group. The primary objective was to investigate overall survival (OS) and disease-free survival (DFS) between the CT and RT groups. Grade 3 or worse adverse events were also presented in the present study.

Results

A total of 145 eligible patients were included. Among these patients, 97 patients underwent adjuvant CT and 48 patients underwent adjuvant RT (RT±CT). The median follow-up was 47.2 months, and the five-year OS rate was 92.7% in the CT group and 88.6 % in the RT group [hazard ratio (HR): 0.81, 95% confidence interval (CI): 0.22–2.99). The 5-year DFS rate for the two groups was 85.7% and 80.2%, respectively (HR: 0.82, 95% CI: 0.33–2.05). The cumulative incidence of local-regional disease recurrence at 60 months of follow-up was 6.2% in the CT group and 6.3% in the RT group (HR=1.11; 95%CI: 0.28–4.35). The cumulative incidence of distant recurrence at 60 months of follow-up was 5.2% in the CT group and 10.4% in the RT group (HR=0.65; 95%CI: 0.19–2.24). Both groups of patients were well-tolerant, and the only grade 3 or worse adverse events were neutropenia and thrombocytopenia.

Conclusion

There was no difference in efficacy for adjuvant CT or adjuvant RT (RT±CT) in high-risk, early-stage endometrioid endometrial carcinoma. CT exhibited a trend of reducing the distant relapse, although there was no significant difference, when compared with adjuvant RT (RT±CT).

Keywords

endometrioid endometrial carcinoma / chemotherapy / radiotherapy

References

[1] WangY, YangJX. Fertility-preserving treatment in women with early endometrial cancer: the Chinese experience. Cancer Manag Res, 2018, 10: 6803-6813

[2] AmantF, MirzaMR, KoskasM, et al.. Cancer of the corpus uteri. Int J Gynaecol Obstet, 2018, 143(Suppl 2): 37-50

[3] SiegelRL, MillerKD, JemalA. Cancer statistics. 2020. CA Cancer J Clin, 2020, 70(1): 7-30

[4] HyunJP, EunJN, SunghoonK, et al.. The benefit of adjuvant chemotherapy combined with postoperative radiotherapy for endometrial cancer: a meta-analysis. Eur J Obstet Gynecol Reprod Biol, 2013, 170(1): 39-44

[5] CreasmanWT, OdicinoF, MaisonneuveP, et al.. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the results of treatment in gynecological cancer. Int J Gynecol Obstet, 2006, 95: S105-S143

[6] MorrowP, BundyBN, KurmanRJ, et al.. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol, 1991, 40: 55-65

[7] JutziL, HoskinsP, LimP, et al.. The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma. Gynecol Oncol, 2013, 131(3): 581-585

[8] CreutzbergCL, van PuttenWL, KoperPC, et al.. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet, 2000, 355: 1404-1415

[9] KeysHM, RobertsJA, BrunettoVL, et al.. Gynecologic Oncology Group (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol, 2004, 92: 744-751

[10] CreutzbergCL, NoutRA, LybeertML, et al.. Fifteen-year radiotherapy outcomes of the randomized PORTEC-I trial for endometrial carcinoma. Radiat Oncol Biol Phys, 2011, 81(4): 631-639

[11] BlakeP, SwartAM, OrtonJASTEC/EN.5 Study Group, et al.. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCICCTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet, 2009, 373: 137-146

[12] SusumuN, SagaeS, UdagawaYJapanese Gynecologic Oncology Group, et al.. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol, 2008, 108(1): 226-259

[13] NoutRA, SmitVT, PutterH, et al.. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet, 2010, 375: 816-839

[14] SongJ, LeT, HopkinsL, et al.. Treatment of early stage high-risk endometrioid-type endometrial cancer and patterns of disease relapse: a retrospective analysis. Adv Radiat Oncol, 2020, 5(5): 910-919

[15] RandallME, FiliaciVL, MussH, et al.. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol, 2006, 24: 36-44

[16] MateiD, FiliaciV, RandallME, et al.. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med, 2019, 380(24): 2317-2326

[17] Gómez-RaposoC, Merino SalvadorM, Aguayo ZamoraC, et al.. Adjuvant chemotherapy in endometrial cancer. Cancer Chemother Pharmacol, 2020, 85(3): 477-486

[18] KodamaJ, SekiN, OjimaY, et al.. Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus. Eur J Obstet Gynecol Reprod Biol, 2017, 131(1): 76-80

[19] AokiY, WatanabeM, AmikuraT, et al.. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer. Gynecologic Oncology, 2004, 94: 333-339

[20] NCCN The NCCN Uterine Neoplasms clinical practice guidelines in oncology (version 2.2021)(2021-05-07) Guidelines Detail (nccn.org)

[21] Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. National Cancer Institute. November 27, 2017. Common Terminology Criteria for Adverse Events (CTCAE) (cancer.gov)

[22] MaggiR, LissoniA, SpinaF, et al.. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer, 2006, 95: 266-271

[23] RandallME, FiliaciVL, MussH, et al.. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol, 2006, 24(1): 36-44

[24] SusumuN, SagaeS, UdagawaYJapanese Gynecologic Oncology Group, et al.. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study. Gynecol Oncol, 2008, 108: 226-233

[25] KandothNC, SchultzN, CherniackAD, et al.. Cancer genome atlas research, integrated genomic characterization of endometrial carcinoma. Nature, 2013, 497: 67-73

[26] MillerDS, FiliaciVL, MannelRS, et al.. Carboplatin and Paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J Clin Oncol, 2020, 38(33): 3841-3850

[27] FrimerM, MillerEM, ShankarV, et al.. Adjuvant pelvic radiation “sandwiched” between paclitaxel/Carboplatin chemotherapy in women with completely resected uterine serous carcinoma: long-term follow-up of a prospective phase 2 trial. Int J Gynecol Cancer, 2018, 28(9): 1781-1788

[28] SecordAA, HavrileskyLJ, O’MalleyDM, et al.. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecol Oncol, 2009, 114: 442-447

[29] de BoerSM, PowellME, MileshkinLPORTEC study group, et al.. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): Final results of an international, open-label, multicenter, randomised, phase 3 trial. Lancet Oncol, 2018, 19: 295-309

[30] de BoerSM, PowellME, MileshkinLPORTEC study group, et al.. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): An open label, multicenter, randomised, phase 3 trial. Lancet Oncol, 2016, 17: 1114-1126

[31] GrevenK, WinterK, UnderhillK, et al.. Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol, 2006, 103: 155-159

[32] HogbergT, SignorelliM, de OliveiraCF, et al.. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer—results from two randomised studies. Eur J Cancer, 2010, 46: 2422-2431

[33] McMeekinDS, FiliaciVL, ThigpenJT, et al.. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a gynecologic oncology group study. Gynecol Oncol, 2007, 106: 16-22